0001562180-22-005001.txt : 20220610 0001562180-22-005001.hdr.sgml : 20220610 20220610081154 ACCESSION NUMBER: 0001562180-22-005001 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20220608 FILED AS OF DATE: 20220610 DATE AS OF CHANGE: 20220610 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Spellman David A CENTRAL INDEX KEY: 0001733204 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36352 FILM NUMBER: 221007679 MAIL ADDRESS: STREET 1: 840 MEMORIAL DRIVE CITY: CAMBRIDGE STATE: MA ZIP: 02139 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Akebia Therapeutics, Inc. CENTRAL INDEX KEY: 0001517022 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 208756903 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 245 FIRST STREET CITY: CAMBRIDGE STATE: MA ZIP: 02142 BUSINESS PHONE: 617-871-2098 MAIL ADDRESS: STREET 1: 245 FIRST STREET CITY: CAMBRIDGE STATE: MA ZIP: 02142 4 1 primarydocument.xml PRIMARY DOCUMENT X0306 4 2022-06-08 false 0001517022 Akebia Therapeutics, Inc. AKBA 0001733204 Spellman David A C/O AKEBIA THERAPEUTICS, INC. 245 FIRST STREET CAMBRIDGE MA 02142 false true false false SVP, CFO and Treasurer Common Stock 2022-06-08 4 A false 200000.00 0.00 A 328599.00 D Stock Option (Right to buy) 0.45 2022-06-08 4 A false 200000.00 0.00 A 2023-05-12 2032-06-08 Common Stock 200000.00 200000.00 D The restricted stock units (the "RSUs") were granted by the Issuer pursuant to its 2014 Incentive Plan, as amended (the "2014 Plan"). The RSUs will vest in full (100%) on May 12, 2023, subject to the Reporting Person's continued service with the Issuer on such vesting date. The option to purchase shares of the Issuer's common stock ("the Stock Option") was granted by the Issuer pursuant to the 2014 Plan. The Stock Option will vest and become exercisable in full (100%) on May 12, 2023, subject to the Reporting Person's continued service with the Issuer on such vesting date. /s/ Carolyn Rucci, attorney-in-fact for David A. Spellman 2022-06-10